Camilla F.
- Country
- Italy
- Department
- Unità di Ematologia
Research Overview
- Long-term Safety and Efficacy Evaluation of Danicopan as an Add-on to Complement Component 5 Inhibitors in Paroxysmal Nocturnal Hemoglobinuria Patients
- Evaluation of Long-Term Safety and Tolerability of Iptacopan in Patients with Paroxysmal Nocturnal Hemoglobinuria Post-Phase II/III Studies
- Phase 3 Study of Ravulizumab in Thrombotic Microangiopathy Post-Hematopoietic Stem Cell Transplant in Adults and Adolescents
Data & Insights
Has run more than one trial at 16 of 75 partner sites.
Specializations
Non-Small Cell Lung Cancer and Precision Thoracic Oncology
Clinical research activity is centered on non-small cell lung cancer, including advanced, metastatic, and resected disease, with interest in EGFR-mutated, KRAS G12C-mutated, HER2-altered, and PD-L1-selected populations.
- Immunotherapy combinations
- Targeted therapy in molecularly defined disease
- Adjuvant treatment in resected lung cancer
The therapeutic focus includes checkpoint inhibition, antibody-based combinations, and biomarker-driven approaches in thoracic malignancies.
Colorectal Cancer and Molecularly Guided Treatment
Research involvement extends to metastatic colorectal cancer and resected colon cancer, with attention to RAS/BRAF status, KRAS G12C mutation, HER2 positivity, and microsatellite instability.
- Anti-EGFR and anti-VEGF strategies
- ctDNA-guided postoperative management
- Combination therapy in advanced disease
There is also interest in treatment optimization for left-sided disease and biomarker-selected metastatic settings.
Lymphoid Malignancies and Hematologic Oncology
The investigator is active in lymphoma and acute leukemia research, including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, Hodgkin lymphoma, and Philadelphia chromosome-positive acute lymphoblastic leukemia.
- Chemo-free regimens
- Maintenance therapy in high-risk disease
- Minimal residual disease-directed treatment
Additional interest includes older and frail patient populations and relapse-focused therapeutic strategies.
Autoimmune and Complement-Mediated Disorders
Clinical work also includes warm autoimmune hemolytic anemia, paroxysmal nocturnal hemoglobinuria, thrombotic thrombocytopenic purpura, and transplant-associated thrombotic microangiopathy.
- Complement inhibition
- Immune-mediated cytopenias
- Thrombotic microangiopathy management
The therapeutic landscape includes targeted control of hemolysis, thrombosis, and immune dysregulation in hematologic disease.
Bladder Cancer, Breast Cancer, and Other Solid Tumors
Additional research interests cover muscle-invasive urothelial carcinoma, high-risk non-muscle-invasive bladder cancer, breast cancer, ovarian cancer, and selected rare solid tumors.
- HER2-directed therapy
- Hormone receptor-positive breast cancer
- Intravesical and systemic immunotherapy
These activities reflect involvement in biomarker-defined treatment strategies across genitourinary and breast oncology.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.